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Objectives. The changes in the serum levels of lipopolysaccharide binding protein (LBP) and sCD14 during cardiac surgery were
followed in this study. Design. Thirty-four patients, 17 in each group, were randomly assigned to coronary artery bypass grafting
surgery performed either with (“on-pump”) or without (“oﬀ-pump”) cardiopulmonary bypass. LBP and sCD14 were evaluated
by ELISA. Results. The serum levels of LBP were gradually increased from the 1st postoperative day and reached their maximum
on the 3rd postoperative day in both “on-pump” and “oﬀ-pump” patients (30.33±9.96 μg/mL; 37.99±16.58 μg/mL), respectively.
There were no signiﬁcant diﬀerences between “on-pump” and “oﬀ-pump” patients regarding LBP. The signiﬁcantly increased
levels of sCD14 from the 1st up to the 7th postoperative day in both “on-pump” and “oﬀ-pump” patients were found with no
signiﬁcant diﬀerences between these groups. No correlations between LBP and sCD14 and IL-6, CRP and long pentraxin PTX3
levels were found. Conclusions. The levels of LBP and sCD14 are elevated in cardiac surgical patients being similar in both groups.
These molecules are not produced as acute phase proteins in these patients.
Copyright © 2007 Manuela Kudlova et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Numerous events, potentialy generating inﬂammatory re-
sponse, are induced during cardiac surgical operation on the
open heart. Amongst them, the combination of surgical in-
jury, mechanical manipulation with the heart, the contact of
blood components with artiﬁcial surfaces of the cardiopul-
monarybypasscircuit,transientendotoxemia,andischemia-
reperfusion injury of the heart and lungs are relevant [1, 2].
The systemic inﬂammatory response syndrome (SIRS)
viewed as basically useful has been conserved during evolu-
tion in order to provide support for the host to survive in
an unfriendly environment, such as strenuous exercise of the
“ﬁght” or “ﬂight” nature, multiple injuries or burns, infec-
tions or, more recently, major surgery. Whichever the under-
lying case, tight control of every step of the inﬂammatory re-
a c t i o n sm u s tb ee x e c u t e db o t ho nl o c a la n do ns y s t e m i cl e v e l
whereactivitiesoftheneuroimmune,endocrine,andcircula-
torysystemsoverlap.Ifthiscontrolfails,morbidity andmor-
tality increase dramatically [3].
Thepresenceofbacteriallipopolysaccharide(LPS)oren-
dotoxininsystemiccirculationissensedasaverystrongdan-
gerpathogenassociatedmolecularpattern(PAMP)byinnate
immunity. This identiﬁcation could be followed by an ex-
agerated and sometimes overwhelming systemic inﬂamma-
tory reaction [4].Incardiacsurgicalpatients,transientendo-
toxemia is a manifestation of insuﬃcient blood supply to the
splanchnic vascular bed after a substantial amount of blood
volume has been diverted from the patient’s own vasculature
intothetubingcircuitoftheheart-lungmachine.Gutwallis-
chemia results in an increase of villous capillary permeability
with ensuing translocation of lipopolysaccharide or even of
the patient’s own enteral ﬂora into the systemic circulation.
The presence of LPS is identiﬁed by numerous phylo-
genetically highly conserved receptors of innate immunity
which are called pattern recognition receptors (PRRs). PRRs
are either humoral or membrane molecules which are some-
times shed into the body ﬂuids. The crucial role in the iden-
tiﬁcation of LPS is devoted to the humoral lipopolysaccha-
ride binding protein (LBP) and two membrane receptors2 Mediators of Inﬂammation
CD14 and toll-like receptor-4 (TLR-4, CD284), respectively.
All these molecules are working in concert providing stim-
ulatory signals to innate immunity cells such as monocyte-
macrophages and granulocytes [5]. However, the former two
molecules display a dual role in an inﬂammatory reaction.
While present in plasma in low concentrations, CD14 be-
ing in the soluble form, early during inﬂammatory response,
LBP and sCD14 are serving as a part of an early alarm sys-
tem aimed at recognizing and binding of LPS and other dan-
ger signals, and thus enhancing the activation of the immune
system. In the late phase, both sCD14 and LBP could play
a role by preventing the lethal side eﬀects of overwhelming
inﬂammatory reaction induces by the presence of “danger.”
This study was aimed to follow the serum levels of LBP
and sCD14 in cardiac surgical patients undergoing coronary
artery bypass grafting (CABG) either with the use of car-
diopulmonary bypass (on-pump) or without the use of car-
diopulmonary bypass (oﬀ-pump). The levels of these mark-
ers immediately after surgery and up to seventh postopera-
tive days were compared to preoperative level. Whereas LBP
is recognized as a typical acute phase protein principally syn-
thesized by hepatocytes, sCD14 molecules are either pro-
duced de novo as acute phase protein or are released into
body ﬂuids by shedding from cell surfaces. To ascertain the
sources of sCD14, its level was correlated to the level of IL-6
which is the most potent stimulus for liver synthesis of acute
phase proteins and to the levels of two pentraxins; C-reactive
protein (CRP) and long pentraxin (PTX3), respectively.
2. PATIENTS AND METHODS
Fortypatients(31male,meanage67.9±9and9female,mean
age66.4±6.4,collectivemeanage67.6±8.5y ears)r eferr edt o
ﬁrst-time coronary artery bypass grafting (CABG) were en-
rolled in this study. Patients underwent either conventional
myocardial revascularization with cardiopulmonary bypass
and cardioplegic arrest of the heart (on-pump, n = 2, 16
male, 4 females, mean age 69.4 ± 7) or beating heart surgery
(oﬀ-pump, n = 2, 15 males, 5 females, mean age 65.9 ±9.7).
Patients in both groups were comparable in age, pre-
operative left ventricular ejection fraction (median 0.65 in
on-pump, 0.65 in oﬀ-pump patients, resp.) and the num-
ber of performed coronary anastomoses (median 2.0 in on-
pump, 2.0 in oﬀ-pump, resp.). All patients had been tak-
ing aspirin 100mg in one daily dose, which was stopped
for ﬁve days preceding the operation. Patients treated with
anti-inﬂammatoryagents,eithersteroidsorNSAID,wereex-
cluded from the study, as were patients with serum creati-
nine ≥ 130μmol/L or with hepatic disorders. No patients
were known to suﬀer from concomitant malignancies. Pa-
tients with active infectious diseases are not admitted to elec-
tive CABG in our department. The study protocol was ap-
proved by the Ethics Committee of the University Hospital
in Hradec Kr´ alov´ e. All participants were informed in detail
about the purpose of the study both orally and in writing.
They were free to ask any questions. One person refused to
participate for reasons he would not specify. All active sub-
jects have given written informed consent.
Cardiopulmonary bypass, oﬀ-pump technique and anes-
thesiological management have been recently described in
detail elsewhere [6].
3. BLOOD SAMPLING
Venous blood (central venous blood from arteria pul-
monalis, peripheral venous blood from an antebrachial vein)
was withdrawn in the operating room and on the ﬁrst post-
operative day in the ICU. Afterwards, only peripheral venous
blood was taken due to the removal from the patients’ vas-
cular bed of all superﬂuous indwelling cannulas. Since there
were practically no diﬀerences in results representative of
bloodsamplesoriginatingfromtherespectivesamplingsites,
for the sake of clarity only values obtained from the periph-
eral venous blood are indicated as results representative of
theentireperiodofinvestigation.Sampleswerecollectedinto
tubes manufactured by Greiner, Germany.
In both on-pump and oﬀ-pump patients, blood was
withdrawn at the following time points:
(i) introductiontoanaesthesia,whichinbothgroupsrep-
resented the baseline or reference value for all param-
eters measured thereafter;
(ii) after termination of the operation;
(iii) the ﬁrst postoperative day;
(iv) the third postoperative day;
(v) the seventh postoperative day.
3.1. Bloodsampleanalysis
Untreated blood samples were allowed to clot at room tem-
perature. Serum samples were obtained after centrifuga-
tion (2000g per 8 minutes), aliquoted and immediately
freezed. Samples were thawed only once. Serum level of LBP
was determined by ELISA kit, cat.number HK315, HyCult
biotechnology b.v., The Netherlands. Serum level of sCD14
was evaluated by sCD14 EASIA kit, cat.number KAS0231,
BioSource Europe S.A., Belgium. IL-6 was quantitatively
measured by commercially available ELISA kit (BenderMed
Systems)accordingmanufacturer’sinstructions.Resultswere
evaluated by spectrophotometry at 450nm (Multiscan pho-
tometer) using Genesis software. CRP was assessed by im-
munonephelometry on IMAGE 800 (Beckman). PTX3 was
detected using detection set (Alexis Biochemicals, Switzer-
land) cat.no. ALX-850-299-KI01 for sandwich ELISA ap-
plication that provided capture monoclonal antibody to
PTX3 (700ng/mL), detection polyclonal antibody to PTX3
(25ng/mL), and recombinant PTX3 (standard). Plates (96
wells, NuncmaxiSorb 446612) were read at 405nm by an
automatic reader (Multiscan photometer) and evaluated by
Genesis software.
3.2. Statistics
Serum level changes within a time and diﬀerences between
both groups of patients were compared by two-way analysis
of variance for repeated measures and Fisher’s post hoc test.
Results are expressed as medians and quartiles. RelationshipsManuela Kudlova et al. 3
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Figure 1: Comparison between serum levels of LBP in “on-”a n d
“oﬀ-pump” patients F (1.32) = 1 .96; P<.l75.
between concentrations of diﬀerent cytokines were assessed
using Pearson’s correlation. Probability values of <.05 were
considered statistically signiﬁcant. Statistical analyses were
performed with Statistica 6 software (StatSoft, USA).
4. RESULTS
4.1. ChangesintheserumlevelofLBP
The baseline preoperative levels of LBP to which LBP con-
centrations were statistically compared were nearly identical
in both on-pump and oﬀ-pump patients (6.25±5.12μg/mL;
7.61 ± 4.79μg/mL, resp.). The same situation was found af-
ter ﬁnishing surgery indicating that LBP levels are not inﬂu-
enced neither by surgery itself nor by cardiopulmonary by-
pass. The sharp statistically signiﬁcant increase of LBP con-
centrations was found on the 1st postoperative day in both
groups of patients. The maximal level of LBP was reached on
the 3rd postoperative day in both on-pump and oﬀ-pump
patients(30.33±9.96μg/mL;37.99±16.58μg/mL,resp.).The
serum levels of LBP declined therafter being still signiﬁcantly
higher on the 7th postoperative day in both on-pump and
oﬀ-pump patients (18.11±9.96μg/mL; 20.15±13.79μg/mL,
resp.). Suprisingly, the concentrations of LBP were slightly
higher in oﬀ-pump patients comparing with on-pump pa-
tients. However, the statistical signiﬁcance was not reached
comparingon-pumpandoﬀ-pumppatients(P<.1715).Re-
sults are shown in Figure 1.
To test the hypothesis that LBP is serving as one of
acute phase proteins, the correlation between serum levels
of LBP and IL-6 which is the principal cytokine regulating
acutephaseproteinsbyhepatocytes,andthetwomembersof
prototypic pentraxin family acute phase proteins, C-reactive
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Figure 2: Comparison between serum levels of sCDI4 in “on-”a n d
“oﬀ-pump” patients F (1.32) = 0.86; P<.4I7.
proteins, and long pentraxin 3, respectively, were tested. No
correlations were found thus rejecting our hypothesis (data
are not shown).
4.2. ChangesintheserumlevelofsCD14
The baseline preoperative levels of sCD14 to which sCD14
concentrations were statistically compared were very similar
in both on-pump and oﬀ-pump patients (7.29±3.32μg/mL;
8.30 ± 4.26μg/mL, resp.). There was a slight, nonsigniﬁcant
decrease of sCD14 level in on-pump patients after surgery
(P = .170), whereas sCD14 concentration was nonsigniﬁ-
cantly elevated in oﬀ-pump patients at that time. There were
diﬀerent trends in LBP concentration in on-pump and oﬀ-
pump patients during postoperative period. The maximum
ofsCD14concentrationinon-pumppatientswasreachedon
the 1st postoperative day (11.30 ± 4.93μg/mL; P = .0001)
followed by a gradual decrease up to the 7th postopera-
tive day (9.41 ± 4.80μg/mL; P = .009) being still above
preoperative baseline level. In contrast, there was a grad-
ual increase of sCD14 serum level from the end of surgery
up to the 7th postoperative day when the maximum was
reached (11.05±4.57μg/mL; P = .002). In spite of these dif-
ferences, no signiﬁcant diﬀerencies between on-pump and
oﬀ-patients were found (P = .417). Results are shown in
Figure 2.
To test the hypothesis that sCD14 is serving as one of
acute phase proteins, the correlation between serum levels
of sCD14 and IL-6 which is the principal cytokine regulat-
ingacutephaseproteinsbyhepatocytes,andtwomembersof
prototypic pentraxin family acute phase proteins, C-reactive
proteins, and long pentraxin 3, respectively, were tested. No4 Mediators of Inﬂammation
correlations were found thus rejecting our hypothesis (data
are not shown).
5. DISCUSSION
Numerousdangerpatterns,bothendogenousandexogenous
origins, are generated in patients undergoing cardiac surgical
operation.Sensingofthesedangerpatternsviainnateimmu-
nity pattern recognition receptors (PRRs) is followed by the
development of inﬂammatory response. Numerous PRRsare
now fully characterized. Amongst them LBP, CD14, MD-2,
and TLR-4 are implicated as key factors in innate immunity
cells activation by bacterial endotoxin [7].
LBP is a 50-kDa polypeptide mainly synthesized in hepa-
tocytes and is released as a 60-kDa glycoprotein into blood
stream after glycosylation. Other sources of LBP synthesis
have been identiﬁed, such as epithelial cells of mucosa as well
as the smooth muscle cells of lung arteries, and heart muscle
cells. The amino acid sequence of LBP revealed substantial
homology to bactericidal permeability increasing (BPI) pro-
tein, another LPS-binding protein originated in innate im-
munity.
LBP binds to the amphipathic lipid A moieties of LPS
with high aﬃnity and has been shown to facilite the pro-
cess of LPS monomerization and subsequent presentation
to other cellular and humoral binding sites. It catalyzes
the transfer of LPS to a binding site of membrane-bound
mCD14, which represents one part of cellular-LPS recep-
tor. Adding LBP to a serum-free cell system enhances the
LPS-mediated stimulation of CD14-positive cells 100- to
1000-fold. In addition, LBP transfers LPS to soluble sCD14
molecule [8].
We found signiﬁcantly increased serum levels of LBP in
our cardiac surgical patients from the ﬁrst postoperative day
up to the 7th postoperative day in comparison with preop-
erative level. The maximum, approximately 30μg/Ml, was
reached on the 3rd postoperative day with subsequent de-
cline in both oﬀ-pump and on-pump patients. It was supriz-
ing to recognize that LBP level was even higher in oﬀ-pump
patients, but no signiﬁcant diﬀerences between on-pump
and oﬀ-pump patients were found. We have no informations
regarding LBP measurement in cardiac surgical patients to
compare our results. The only one exception is the work by
Fransen et al. [9] who followed LBP concentrations in on-
pump patients. Unfortunately, their observation period was
only up to 18 hours after declamping aorta. They found sig-
niﬁcantly increased LBP level at the 8th hour with subse-
quent increase at the 18th hour after start of reperfusion but
maximum was not reached in their observation period.
Several in vivo and in vitro experiments demonstrated
that LBP is a secretory class 1 acute phase protein whose
gene is transcriptionaly activated by cytokine-inducible nu-
clear proteins. The transcriptional regulation is induced by
IL-1 alone or synergistically by IL-1 and IL-6 leading to a
maximumLBPconcentrationwithin24–48hoursafterstim-
ulation. This response can be strongly enhanced by TNF-
α and dexamethasone [10]. The dynamics of LBP concen-
trations in our cardiac surgical patients was resembling this
kinetics but with prolongation up to the 7th postoperative
day. To test the eﬀect of proinﬂammatory cytokines on LBP
synthesis, the level LBP was correlated with the level of IL-6
which is a principal cytokine regulating acute phase proteins
synthesis in the liver. No such correlation was found (data
are not shown). The possibility that LBP concentration in
blood is inﬂuenced by exogenous corticosteroid is also un-
likely. There was no signiﬁcant diﬀerence between on-pump
and oﬀ-pump patients despite the fact that former patient’s
group is exposed to methylprednisolone which is a standard
component in CPB ﬂuid used in our setting.
In humans LBP is constitutively in serum at concentra-
tions of 5–15μg/mL. It is in a good concordance with its
baseline level in our cardiac surgical patients. Its level is
raised 10- to 50-fold during the acute phase reaction [11].
The similar ﬁndings were revealed by us in our patients. In
contrast to C-reactive protein which level is peaked at the
3rd day in our patients and then rapidly declined, increased
level of LBP is sustained up to the 7th postoperative day.
It probably reﬂects the dual role of LBP in an inﬂamma-
tory reaction. Whereas serving as a potent pattern recogni-
tion receptor at low concentrations early during inﬂamma-
tiontoamplifytheimmuneresponserendering,forexample,
TNF-α production in macrophages, high concentrations in-
hibitsdanger-pattern-inducedhostcellactivation[11].Itcan
be partly explained by the ability of LBP to transfer LPS to
serum lipoproteins thus neutralizing the bioactivity of LPS.
LPShasbeenshowntobephysicallyassociatedwithapoA-or
apoB-containing lipoproteins and to transfer LPS into high-
(HDL) and low-density lipoproteins (LDL) resulting in the
clearance of LPS from the bloodstream. These capabilities
were also reported for very-low-density lipoprotein (VLDL)
and chylomicrons [12].
Up to now, few studies have been published evaluating
the value of LBP as a diagnostic marker in patients with SIRS
of noninfectious versus infectious origin and as potential
prognostic marker predicting outcome [13]. These results
can not be proven in our cardiac surgical patients because
no cultivation-conﬁrmed bacterial infections were found in
this group. Information regarding LBP level during cardiac
surgery are very sparse. It is reported by Vreugdenhil et al.
[12] that plasma level of LBP is gradually increased from the
8th to 18th hour after declamping aorta but the maxim was
not reached in their observation period. It is resembling our
data but in our patients the maximum in LBP production
was reached on the 3rd postoperative day. The role of LBP
as acute phase proteins is unlikely in our cardiac surgical pa-
tients becauseno correlations witheitherIL-6, CRP,orPTX3
were found. It is extremly interesting that no signiﬁcant dif-
ferences in the serum level of LBP between on-pump and
oﬀ-pump patients were found in our study. It is generally
assumed that splanchnic hypoperfusion during extracorpo-
real circulation together with steady laminar blood ﬂow that
is generated by the heart-lung machine instead of the pul-
sative blood ﬂow generated by each cardiac contraction, re-
sult in gut wall ischemia, subsequent increase of villous cap-
illary permeability and transient endotoxemia. It is supposed
that these changes are not so profound in oﬀ-pump patients.
Lack of diﬀerences in LBP concentration between on-pump
and oﬀ-pump patients could be interpreted in at least twoManuela Kudlova et al. 5
ways. First, the intensity of the exposition to bacterial danger
pattern is similar in both on-pump and oﬀ-pump patients.
Second, LBP production is stimulated by another still un-
known danger pattern which is identical in both on-pump
and oﬀ-pump patients.
The second aim of our study was to follow the changes
of soluble form of CD14 molecule (sCD14) during cardiac
surgical operation. CD14 is a glycosylphosphatidyl-inositol-
anchored protein constitutively expressed on the surface
of various cells, including monocytes, macrophages, neu-
trophils, B-cells, dendritic cells, as well as several other cell
types of nonhematopoietic origin. Aside of this membrane-
bound state, CD14 is also found in a circulating soluble form
[14]. CD14 molecule is the part of a receptor system of in-
nate immunity cells to identify danger patterns of both ex-
ogenous and endogenous origin. This system is represented
by the combined actions of the membrane-bound isoform
of CD14 with the central transmembrane signaling unit of
TLR-4 and the accessory protein MD-2 [15].
Two opposite functions have been described for sCD14.
It can either reduce endotoxin-induced activities by com-
peting with mCD14 for LPS binding or mediates the LPS-
induced activation of non-CD14-expressing endothelial, ep-
ithelial, and smooth muscle cells. In addition, CD14 may
function as a receptor for other microbial products, human
heat shock proteins Hsp60, and other endogenous ligands
such as ceramides, phospholipids, and modiﬁed lipoproteins
[16].
We found signiﬁcantly increased serum level of sCD14
from the 1st up to 7th postoperative days compared to the
preoperativevaluesinbothon-pumpandoﬀ-pumppatients.
Suprisingly, there are no signiﬁcant diﬀerences between on-
pump and oﬀ-pump patients. Evenmore, while reaching the
maximumonthe1stpostoperative dayin on-pumppatients,
sCD14 level was gradually increasing in oﬀ-pump patients
up to the 7th postoperative day (end of observation). It is
not easy to discuss our ﬁndings. The level of sCD14 is not
commonly assessed in cardiac surgical patients. It could be
possible to extrapolate from patients undergoing major elec-
tive abdominal surgery as was reported by Hiki et al. [17].
They found slight decrease 6 hours after incision of skin,
reaching the maximum on the 1st postoperative day there-
after decline to approximately baseline preoperative level on
the 10th postoperative day. This pattern is resembling our
oﬀ-pump patients with the exception that maximal concen-
tration in our patients was slightly higher (11.3μg/mL versus
9.4μg/mL).
Several clinical studies have reported elevated serum lev-
els of sCD14 in various inﬂammatory conditions such as
Kawasaki disease [18]. Furthermore, correlation between
sCD14 and severity of the trauma in polytraumatized pa-
tients have also been published [19]. Besides its function in
LPS signaling, sCD14 might therefore play a role in inﬂam-
matory processes by controlling the immune system level of
response. It has recently been demonstrated that sCD14 is a
regulatoryfactorcapableofmodulatingcellularandhumoral
immune responses by interacting directly with T and B cells
[20]. Moreover, it has been suggested that sCD14 could be an
acute phase protein, because apart from proteases-mediated
shedding,sCD14isalsoproducedbyhepatocytes,whichrep-
resent the major source of acute phase proteins. Indeed, Bas
et al. [14] in their clinical and experimental studies clearly
showed that in patients suﬀering from rheumatoid arthritis,
serum level of sCD14 did not correlate with the number of
leukocytes, thus excluding an important source from leuko-
cyte membrane-bound CD14, by protease-mediated shed-
ding. In contrast, serum levels of sCD14 in these patients
correlated with those of C-reactive protein, a classical acute
phase protein, and IL-6, a cytokine known to regulate the
synthesis of APP in the liver. We also sought for such correla-
tions in our cardiac surgical patients. No statistically signif-
icant correlations between serum level of sCD14 and either
IL-6 concentration or CRP and PTX3 levels were found in
our study. It could be concluded from our results that sCD14
is not produced as one of acute phase proteins in cardiac
surgery. The source of sCD14 in these patients remains enig-
matic. Whether sCD14 in cardiac surgery originates mainly
from leukocytes by protese-mediated shedding warrants fur-
ther investigations.
In conclusion, we found signiﬁcantly increased levels of
bothsCD14andLBPintheearlypostoperativeperiodincar-
diacsurgicalpatients.Wefoundnosigniﬁcantdiﬀerencesbe-
tweenon-pump andoﬀ-pump patientsin theserumlevelsof
these parameters. Finally, both LBP and sCD14 molecules do
not seem to act as acute phase proteins in cardiac surgical
patients.
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ABBREVIATIONS
IL: Interleukin
LBP: Lipopolysaccharide binding protein
LPS: Lipopolysaccharide
PAMP: Pathogen associated molecular patterns
PRR: Pattern recognition receptors
PTX3: Long pentraxin 3
sCD14: Soluble form of CD14 molecule
SIRS: Systemic inﬂammatory response syndrome
TLR: Toll-like receptors
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